

WRHA HAZARDOUS MEDICATIONS LIST¹

CYTOTOXIC HAZARDOUS MEDICATIONS			
ado-trastuzumab emtansine afatinib altretamine amsacrine arsenic axitinib azaCITIDine azaTHIOprine ² bendamustine bleomycin bortezomib bosutinib brentuximab vedotin busulfan ² cabazitaxel capecitabine ² CARBOplatin carmustine chlorambucil CISplatin cladribine clofarabine crizotinib cyclophosphamide cytarabine	dabrafenib dacarbazine DACTINomycin dasatinib DAUNOrubicin deferiprone dexrazoxane DOCEtaxel DOXOrubicin epirubicin eribulin erlotinib ² estramustine etoposide floxuridine flucytosine fludarabine fluorouracil ganciclovir gefitinib ² gemcitabine gemtuzumab ozogamicin hydroxyurea	ibrutinib IDArubicin ifosfamide imatinib ² irinotecan lapatinib lenalidomide lomustine mechlorethamine melphalan mercaptopurine methotrexate ² mitoMYcin mitoXANtrone nelarabine nilotinib oxaliplatin PACLitaxel pazopanib PEMEtrexed pentostatin phenoxybenzamine procarbazine ²	raltitrexed regorafenib romidepsin ruxolitinib SORAFenib streptozocin SUNItinib temozolomide temsirolimus teniposide thalidomide thioguanine thiotepa topotecan trametinib valGANciclovir ² valrubicin vandetanib vemurafenib vinBLAStine vinCRIStine vinorelbine vorinostat
SEE PAGE 2 FOR NON-CYTOTOXIC HAZARDOUS MEDICATIONS			

1. The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
 - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
 - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec[®] which contains misoprostol and diclofenac).
 - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
 - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
2. "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings*, 2014 for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

Revised and Effective February 2016

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php

WRHA HAZARDOUS MEDICATIONS LIST¹

NON - CYTOTOXIC HAZARDOUS MEDICATIONS		
abiraterone acitretin alitretinoin ambrisentan anastrozole ² bacillus calmette guerin ³ (bladder instillation only) bexarotene bicalutamide ² bosentan buserelin cetorelix choriogonadotropin alfa cidofovir clomiPHENE colchicine ² cycloSPORINE cyproterone degarelix dinoprostone ² dutasteride everolimus exemestane ²	finasteride ² fingolimod fluoxymesterone ² flutamide ² foscarnet fulvestrant ganirelix goserelin iloprost ISOtretinoin leflunomide ² letrozole ² leuprolide megestrol ² methacholine methylTESTOSTERone mifepristone misoprostol ² mitotane mycophenolate mofetil mycophenolic acid	nafarelin nilutamide ² oxandrolone ² pentamidine (aerosol only) podofilox podophyllum resin raloxifene ² ribavirin sirolimus tacrolimus tamoxifen ² testosterone tretinoin trifluridine triptorelin
SEE PAGE 1 FOR CYTOTOXIC HAZARDOUS MEDICATIONS		

1. The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
 - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
 - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec® which contains misoprostol and diclofenac).
 - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
 - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
2. "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.
3. Bacillus Calmette Guerin (BCG), when used for bladder instillation, shall be prepared following the instructions provided with the closed system reconstitution kit and in the *Bladder Instillation of Bacillus Calmette-Guerin (BCG) & BCG/Interferon for the Treatment of Bladder Cancer Directive*. See: <http://home.wrha.mb.ca/prog/surgery/files/BCGOPERATIVEDIRECTIVE.pdf>

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings*, 2014 for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

Revised and Effective February 2016

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php